A multidisciplinary approach to dosing nusinersen for spinal muscular atrophy

BACKGROUND: In December 2016, nusinersen gained FDA approval as the first pharmacologic treatment for spinal muscular atrophy (SMA), a disorder of motor neurons and the leading genetic cause of infant mortality. Nusinersen's intrathecal delivery requirement, strict dosage protocol, and accelera...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neurol Clin Pract
Main Authors: Zingariello, Carla D., Brandsema, John, Drum, Elizabeth, Henderson, Alicia A., Dubow, Scott, Glanzman, Allan M., Mayer, Oscar, Yum, Sabrina W., Kichula, Elizabeth A.
Formato: Artigo
Idioma:Inglês
Publicado em: Lippincott Williams & Wilkins 2019
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6814423/
https://ncbi.nlm.nih.gov/pubmed/31750028
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/CPJ.0000000000000718
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados